← Oncology Approval Tracker

FDA DECISION ·

Tukysa + trastuzumab + capecitabine

tucatinib + trastuzumab + capecitabine · Seattle Genetics

FDA approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable advanced or metastatic HER2-positive breast cancer, including those with brain metastases, after at least one HER2-directed regimen in the metastatic setting.

LAMPGEN ANALYSIS

Why it matters

Established a HER2 regimen backed by prospective evidence in patients with brain metastases.

What research teams should watch

Record intracranial disease and prior HER2 treatment and align brain imaging with response assessments.

PRIMARY RECORDS

Sources